Abstract: Aspartic acid derivatives of the formula ##STR1## in which X denotes, for example, ##STR2## and R denotes, for example, cyclohexylamino, have useful pharmacological properties.

Abstract: The present invention relates to 2,4-dioxoimidazolidine compounds of the formula I ##STR1## a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.

Abstract: The invention relates to compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Y have the meanings indicated in Claim 1, to processes for their preparation and their use as active pharmacological substances.

Abstract: The invention relates to pharmacologically active substituted 3-aminosydnone imines of the general formula I ##STR1## in which n denotes 0 or 1, and their pharmacologically acceptable salts and acid addition salts, and to a process for the preparation of the compounds according to the invention and their use.

Abstract: Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sup.1 denotes e.g. hydrogen;R.sup.2 denotes e.g. an alkyl radical;at least two of the radicals R.sup.3, R.sup.4, R.sup.5 and R.sup.6 denote alkyl radicals and the others denote hydrogen, are prepared by cyclization of a compound of the formula II ##STR2## and, if appropriate, subsequent acylation, and have useful pharmacological properties.

Abstract: The present invention relates to pharmacologically active substituted 3-dicyclohexylaminosydnone imines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sup.1 denotes hydrogen or the radical --COR.sup.2 and R.sup.2 denotes (C.sub.1 to C.sub.4)-alkyl, (C.sub.1 to C.sub.4)alkoxy-(C.sub.1 to C.sub.4)alkyl, (C.sub.1 to C.sub.4) alkoxy, (C.sub.1 to C.sub.4)alkoxy-(C.sub.1 to C.sub.4 )alkoxy, (C.sub.5 to C.sub.7)cycloalkyl, phenyl, a phenyl radical which is mono-, di- or trisubstituted by 1 to 3 halogen atoms and/or 1 to 3 alkyl radicals having 1 to 4 C atoms and/or 1 to 3 alkoxy radicals having 1 to 4 C atoms, a nicotinoyl radical or an allylmercaptoacetyl radical, and to a process for the preparation of the compounds according to the invention and their use.

Abstract: The invention relates to pharmacologically active substituted 3-aminosydnone imines of the general formula I ##STR1## in which R.sup.1 denotes (C.sub.1 -C.sub.4)-alkyl, di-(C.sub.1 -C.sub.4)-alkylamino or (C.sub.6 -C.sub.12)-aryl, which can optionally be substituted by (C.sub.1 -C.sub.4)-alkyl;R.sup.2 denotes hydrogen or COR.sup.3 and R.sup.3 denotes (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy, (C.sub.1 -C.sub.4)-alkoxy-(C.sub.1 -C.sub.4)-alkyl, acetoxy-(C.sub.1 -C.sub.4)-alkyl, (C.sub.6 -C.sub.12)-aryl, which can be substituted by (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-alkoxy, pyridyl, pyridyl(C.sub.1 -C.sub.4)alkyl or (C.sub.3 -C.sub.8)-cycloalkyland their pharmacologically acceptable acid addition salts.

Abstract: Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes, for example, --CH.sub.2 --,R.sup.1 denotes hydrogen or the radical --COR.sup.5,R.sup.2, R.sup.3 denote alkyl having 1 to 4 C atoms,R.sup.5 denotes, for example, an aliphatic radical having 1 to 4 C atoms,and methods for preparing such compounds by cyclization of a compound of the formula II ##STR2## and if desired subsequent acylation. The invention also includes formulations containing effective amounts of such compounds, and methods for administering same to patients for the control and prophylaxis of cardiovascular disorders.

Abstract: The 1,2,3,4-oxatriazolium-5-olates of the formula I ##STR1## in which R.sup.1 denotes, for example, (C.sub.2 to C.sub.4)alkyl,R.sup.2 and R.sup.3 denotes (C.sub.1 to C.sub.4)alkyl have useful pharmacological properties.

Abstract: Substituted 3-aminosydnone imines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes an alkylene chain;X denotes one of the groups --O-- or --S--;R.sup.1 denotes e.g. hydrogen;R.sup.2 denotes e.g. an alkyl group,are prepared by cyclization of a compound of the formula II ##STR2## and, if appropriate, subsequent acylation, and have useful pharmacological properties.

Abstract: Substituted 3-aminosydnonimines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, wherein R.sup.1 denotes, for example, alkyl having 1 to 8 C atoms, R.sup.2 denotes hydrogen or the radical --COR.sup.3 and R.sup.3 denotes, for example, an aliphatic radical having 1 to 4 C atoms, are prepared, for example, by cyclization of a compound of the formula II ##STR2## and if appropriate subsequent acylation and have useful pharmacological properties.

Abstract: Substituted allylmercaptoacetylsydnonimines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sub.1 represents a secondary amino group of the formula ##STR2## and X denotes ##STR3## R.sub.2 denotes one of the radicals R.sub.3 OOC--, R.sub.4 SO.sub.2 -- or alkyl having1-4 C atoms,n denotes one of the values 1, 1 or 2,and R.sub.3 denotes alkyl having 1-4 C atoms,and R.sub.4 represents R.sub.3 or (R.sub.3).sub.2 N--, have valuable pharmacological properties.

Abstract: Optically active substituted 3-aminosydnonimines of the general formula I ##STR1## and their pharmacologically acceptable acid addition salts, wherein R.sup.1 denotes, for example, the radical R.sup.3 (R.sup.4)N-,R.sup.2 denotes the radical 1-methoxyethyl (--CH(CH.sub.3)OCH.sub.3), acetoxy-phenyl-methyl (--CH(C.sub.6 H.sub.5)O--COCH.sub.3), 1-(ethoxycarbonyl)-ethoxy (--O--CH.sub.3)CO.sub.2 C.sub.2 H.sub.5),R.sup.3 denotes alkyl(C.sub.1 -C.sub.4) andR.sup.4 denotes for example alkyl(C.sub.1 -C.sub.4),possess valuable pharmaceutical properties.

Abstract: Substituted 4,5-dihydro-3(2H)-pyridazinones of the formula I ##STR1## wherein R, for example, denotes a radical of the formula ##STR2## R.sup.1 and R.sup.2, for example, denote hydrogen or methyl, R.sup.3, for example, denotes 2-methoxy-ethoxy, 3-pyridyl-methoxy, amino-carbonyl-methoxy, hydroxy-carbonyl-methoxy, methyl-thio, (2-methoxy-ethyl)-amino-carbonyl-methoxy, 3-pyridyl-methyl or 5-methyl-1,3,4-oxadiazol-2-yl and R.sup.4, for example, denotes hydrogen, have useful pharmacological properties and can therefore be used for the preparation of pharmacological products.

Abstract: Tetrahydropyridazinones of the formula I ##STR1## wherein R denotes an optionally substituted carbocyclic or heterocyclic radical, R.sup.1 denotes hydrogen; alkyl; aralkyl, which is optionally substituted in the aryl part; or acyl, and R.sup.2 denotes hydrogen; alkyl, which can optionally be substituted; or optionally substituted phenyl; and their acid addition compounds, if these can be prepared.The tetrahydropyridazinone derivatives of the formula I according to the invention and their physiologically acceptable salts exhibit useful pharmacological actions.

Abstract: 1,4-dihydropyridines of the formula I ##STR1## in which R denotes, for example, --CO.sub.2 R.sup.3 or cyano, R.sup.1 denotes, for example, an optionally substituted phenyl, pyridyl or thienyl, R.sup.2 denotes the radical of a 5-membered, optionally substituted, ring having at least one double bond and at least 2 heteroatoms or heteroatom groups from the series comprising O, N, NH and S, and R.sup.3 denotes, for example, alkyl or alkoxyalkyl, and their acid addition salts, have valuable pharmacological properties.

Abstract: Pharmacologically-active 3-aminosydnonimines (which are optionally substituted in the N.sup.6 -position) and their physiologically-acceptable acid-addition salts are compounded into standard dosage-form medicament compositions and are useful for prophylaxis for and treatment of cardiovascular-system disorders, such as high blood pressure and angina pectoris. The 3-aminosydnonimines are 3-[4-(lower alkoxy)carbonylpiperazin-1-yl]sydnonimines and 3-[N-(lower alkyl)-N-(tetrahydro-3-thienyl S,S-dioxide)]-sydnonimines.

Abstract: Pharmacologically-active 3-aminosydnonimines (which are optionally substituted in the N.sup.6 -position) and their physiologically-acceptable acid-addition salts are compounded into standard dosage-form medicament compositions and are useful for prophylaxis for and treatment of cardiovascular-system disorders, such as high blood pressure and angina pectoris. The 3-aminosydnonimines are 3-[4-(lower alkoxy)carbonylpiperazin-1-yl]sydnonimines and 3-[N-(lower alkyl)-N-(tetrahydro-3-thienyl S,S-dioxide)]-sydnonimines.

Abstract: Pharmacologically-valuable 3,4-(bis-substituted)-1,2,5-oxdiazole 2-oxides of formula I ##STR1## [wherein R denotes --NHR.sup.1, --NR.sup.2 R.sup.3, --NHR.sup.4 OR.sup.2, --NHR.sup.5 COR.sup.6 or ##STR2## R.sup.1 denotes alkyl having from 1 to 6 C atoms or cycloalkyl having 4 to 7 ring C atoms, R.sup.2 and R.sup.3 denote alkyl having from 1 to 4 C atoms, R.sup.4 denotes an alkylene radical of the formula --C.sub.n H.sub.2n --(wherein n denotes 2, 3 or 4), R.sup.5 denotes an alkylene radical of the formula --C.sub.m H.sub.2m -- (wherein m denotes 1, 2 or 3), R.sup.6 denotes --OR.sup.2, --NHR.sup.1, --NR.sup.2 R.sup.3 or --NH.sub.2, X denotes --(CH.sub.2).sub.p --, --(CH.sub.2).sub.2 --O--(CH.sub.2).sub.2 -- or ##STR3## and p is 4, 5 of 6] and their pharmacologically-acceptable acid-addition compounds are prepared by elimination of hydrogen chloride from a hydroxamoyl chloride of the formulaR--CO--C(Cl).dbd.NOH (II)and dimerization.